AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8741955
Drug: 7 mg/day
RxNorm normalized name: nicotine 7 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg/day nicotine skin patch for nonsmokers
Trial: 8741955
Drug: Nicotine skin
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine skin patch (both dosages)
Trial: 8741955
Drug: Nicotine skin
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine skin patch (smokers only)
Trial: 12491501
Drug: L-PAM (L-phenylalanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PAM (L-phenylalanine mustard)
Trial: 3917352
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with TM followed by CAF upon failure
Trial: 3917352
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with TM
Trial: 1105174
Drug: L-PAM
RxNorm normalized name: L-PAM
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-PAM
Trial: 28661062
Drug: Haemoglobin trigger
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemoglobin trigger for RBCT < 9.7 g dL-1 (arm A)
Trial: 28661062
Drug: Haemoglobin trigger
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemoglobin trigger for RBCT < lower normal level (female: 11.5 g dL-1, male: 13.1 g dL-1) (arm B)
Trial: 21048970
Drug: Artesunate plus
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate plus amodiaquine (AS+AQ) monthly
Trial: 12383808
Drug: Topical 5‐fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5‐fluorouracil (50 mg/ml for 5 minutes)
Trial: 12383808
Drug: Topical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical mitomycin C (0.2 mg/ml for 2 minutes)
Trial: 10440143
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (1 g/day for 2 days)
Trial: 7580056
Drug: Bushen Jiangu
RxNorm normalized name: Jiang Huang (Curcuma Longa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bushen Jiangu (BSJG) capsule
Trial: 3308737
Drug: Calcium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium treatment
Trial: 2181310
Drug: Melphalan (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melphalan (0.2 mg per kilogram of body weight per day for five days, repeated every four to six weeks for up to 12 cycles)
Trial: 28946522
Drug: Manual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Therapy (MG)
Trial: 25663642
Drug: Daily antioxidant
RxNorm normalized name: Ascorbic Acid/Selenium/Vitamin A/Vitamin E Oral Capsule, Liquid Filled [DAILY ANTIOXIDANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily antioxidant therapy
Trial: 25663642
Drug: Antioxidant therapy
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant therapy in chronic ITP
Trial: 21292056
Drug: Behavioral Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Activation (BA) therapy consisting of eight 30- to 60-minute sessions across 4 weeks
Trial: 15390011
Drug: Levetiracetam (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (titrated to 3,000 mg/day or lower maximal tolerated dose)
Trial: 11243949
Drug: Methylprednisolone (MP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP), 0.5 mg/kg q6h for 3 days
Trial: 11243949
Drug: Methylprednisolone (MP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP), 0.5 mg/kg q6h for 3 days, then tapered and terminated on the tenth day
Trial: 11243949
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (3-day MP treatment)
Trial: 11243949
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10-day MP treatment)
Trial: 9683004
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g oral dosage of glucose
Trial: 778998
Drug: Piribedil in
RxNorm normalized name: piribedil Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piribedil in association with L‐Dopa
Trial: 29756308
Drug: Oral Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Group (OG)
Trial: 24628390
Drug: 5 mg/d
RxNorm normalized name: Arixtra 5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/d folate supplements
Trial: 18570896
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii treatment
Trial: 11251331
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of enoxaparin administered subcutaneously
Trial: 1855737
Drug: Bromocriptine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (2.5 mg twice daily for 1 year)
Trial: 31826368
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (3.4 g) combined with muscle strengthening exercises
Trial: 31826368
Drug: Control (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (1.2 g of starch)
Trial: 26959879
Drug: Flurbiprofen (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (administered before skin incision and at the end of operation), n=30
Trial: 17394653
Drug: Pretreatment intervention
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment intervention designed to enhance treatment motivation, decrease crack use, and prepare for treatment entry.
Trial: 8558187
Drug: VM26 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM26 120 mg/m2 on days 1, 3, and 5 with cisplatin 80 mg/m2 on day 1
Trial: 8558187
Drug: VM26 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM26 360 mg/m2 on day 1 with cisplatin 80 mg/m2 on day 1
Trial: 8558187
Drug: VM26 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM26 120 mg/m2 on days 1, 3, and 5 without cisplatin
Trial: 8558187
Drug: VM26 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM26 360 mg/m2 on day 1 without cisplatin
Trial: 1816217
Drug: Misoprostol 200
RxNorm normalized name: MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 200 micrograms thrice daily
Trial: 30294826
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health therapist intervention (OHTI)
Trial: 25557228
Drug: Methylprednisolone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (2 mg·kg(‐1))
Trial: 24424704
Drug: ZST 1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZST 1.75 mg
Trial: 24424704
Drug: ZST 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZST 3.5 mg
Trial: 22947342
Drug: Health education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health education intervention including measuring daily salt content, estimating 24-hour salt intake, and cooking classes with less salt
Trial: 4934047
Drug: Drug combinations
RxNorm normalized name: Other anti-dementia drug combinations in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug combinations
Trial: 3901821
Drug: Active therapies
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active therapies (Ciramadol and Morphine)
Trial: 29317812
Drug: Indacaterol/glycopyrronium (IND/GLY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily for 4 weeks
Trial: 29317812
Drug: Tiotropium (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (18 μg) once daily for 4 weeks
Trial: 18675765
Drug: Face-to-face medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face medication consultation provided by a community pharmacy resident.
Trial: 16438891
Drug: Breast conserving
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast conserving therapy (BCT)
Trial: 2043493
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide (10 mg/kg iv. loading dose + 7 hours continuous infusion) + lorazepam (2.5 mg x 4 po)
Trial: 2043493
Drug: Low-dose metoclopramide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose metoclopramide (70 mg) + lorazepam (2.5 mg x 2 po) + dehydrobenzperidol (5 mg x 2 im)
Trial: 30626198
Drug: Alcohol and
RxNorm normalized name: Polyvinyl alcohol and povidone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol and other drug (AOD) use
Trial: 30816108
Drug: Apatinib (VEGFR2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (VEGFR2 inhibitor)
Trial: 30535668
Drug: Steroid arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid arm (methylprednisone)
Trial: 25245572
Drug: Lactobacillus paracasei
RxNorm normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus paracasei subsp. paracasei L. casei W8 (1010 cfu)
Trial: 16361302
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo capsules)
Trial: 17094103
Drug: Entacapone 100
RxNorm normalized name: Entacapone
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entacapone 100 mg
Trial: 12060504
Drug: 1% penciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% penciclovir cream
Trial: 12060504
Drug: 3% aciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% aciclovir cream
Trial: 9857648
Drug: Chemotherapy (mitomycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (mitomycin, cisplatin, vinblastine)
Trial: 2225705
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 to 100 mg once a day)
Trial: 2225705
Drug: Enalapril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (2.5 to 40 mg once a day)
Trial: 552658
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg RG 033
Trial: 552658
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg RG 033
Trial: 30666357
Drug: LDH ≥
RxNorm normalized name: Lactate dehydrogenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDH ≥ 618 IU/L
Trial: 28394172
Drug: Shorter total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter total wake time (TWT) before treatment session
Trial: 28394172
Drug: Shorter total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter total wake time (TWT) after treatment session
Trial: 28394172
Drug: Shorter total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter total sleep time (TST) before treatment session
Trial: 28394172
Drug: Shorter total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter total sleep time (TST) after treatment session
Trial: 23430381
Drug: 1.5 L
RxNorm normalized name: NUTREN 1.5 LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 L PEG‐electrolyte solution plus 15 mg of mosapride
Trial: 23430381
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L PEG‐electrolyte solution plus 15 mg of mosapride
Trial: 16934044
Drug: 8-prenylnaringenin (8-PN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-prenylnaringenin (8-PN) 750 mg
Trial: 21839654
Drug: Percutaneous transluminal
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous transluminal angioplasty (PTA) in addition to medical therapy (immediate treatment group - ITG)
Trial: 21839654
Drug: Percutaneous transluminal
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous transluminal angioplasty (PTA) after 6 months of medical therapy alone (delayed treatment group - DTG)
Trial: 21839654
Drug: Magnetic resonance
RxNorm normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic resonance imaging (MRI) results in immediate treatment group (ITG)
Trial: 21839654
Drug: Magnetic resonance
RxNorm normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic resonance imaging (MRI) results in delayed treatment group (DTG)
Trial: 16264053
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy (Continuous Positive Airway Pressure)
Trial: 7826293
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (insulin administration at least three times a day, adjusted based on self-blood glucose monitoring, aiming for normoglycemia)
Trial: 7826293
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (one or two daily insulin injections)
Trial: 305522
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg Biarison
Trial: 305522
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg indometacin
Trial: 305522
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg Biarison (under double blind conditions)
Trial: 30055303
Drug: DNS-7801 solutions
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNS-7801 solutions
Trial: 30055303
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of citrate buffer at pH 3.0 and hydroxypropylbetadex
Trial: 18402630
Drug: Lamotrigine treatment
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine treatment for 8 weeks
Trial: 24796044
Drug: Jingjin acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jingjin acupuncture treatment (including acupuncture on palm side of affected hand, dorsal metacarpophalangeal joints, and proximal interphalangeal joints, once every other day, with electroacupuncture when qi was acquired)
Trial: 24796044
Drug: Jingjin acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jingjin acupuncture treatment
Trial: 20384388
Drug: DRSP 3
RxNorm normalized name: DRSP
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: DRSP 3 mg/EE 30 microg
Trial: 12427152
Drug: Oral l‐folinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral l‐folinic acid at 20 mg/day
Trial: 12427152
Drug: Oral folic
RxNorm normalized name: folic acid Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral folic acid at 15 mg/day
Trial: 30033514
Drug: Spirulina supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina supplement (2 g/day) plus conventional regimen (220 mg/day zinc sulfate, 500 mg/day L-carnitine, and 50 mg/day clomiphene)
Trial: 26956541
Drug: Acupuncture (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (10 treatments over 8 weeks)
Trial: 26956541
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (7 sessions over 8 weeks)
Trial: 24132248
Drug: Galantamine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (up to 24 mg/day)
Trial: 22045595
Drug: TAS-108 40
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-108 40 mg daily
Trial: 22045595
Drug: TAS-108 80
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-108 80 mg daily
Trial: 22045595
Drug: TAS-108 120
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-108 120 mg daily
Trial: 19308365
Drug: C/P (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C/P (60 mg codeine + 1000 mg paracetamol) four times daily
Trial: 19308365
Drug: L+C/P (levomepromazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L+C/P (levomepromazine 5 + 5 + 5 + 10 mg + C/P) four times daily
Trial: 17259517
Drug: Thiazolidinediones (TZDs)
RxNorm normalized name: (±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazolidinediones (TZDs) therapy
Trial: 7515387
Drug: DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (50 mg nightly for 6 months)
Trial: 26472406
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with Ozurdex and macular laser therapy (MLT)
Trial: 26472406
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with Ozurdex and MLT
Trial: 23516656
Drug: Integrated control
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated control strategy including praziquantel chemotherapy, controlling snails, building fences for bovines, safe pastures, and improving health conditions in six intervention villages.
Trial: 23516656
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with routine interventions including praziquantel chemotherapy and controlling snails, without new interventions.
Trial: 19033012
Drug: Zofenopril (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril (30 mg/d)
Trial: 9848785
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 mg/d)
Trial: 8760738
Drug: Combined Antibiotic
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Antibiotic Groups (Amoxycillin and Penicillin V)
Trial: 1313765
Drug: Indomethacin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (150 mg day-1 for three days)
Trial: 1313765
Drug: Cyclosporine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (5 mg kg-1 body weight for five days)
Trial: 3860511
Drug: 0.02% stannous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% stannous fluoride (SnF2) solution using Water Pik
Trial: 30422367
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone in combination with Botulinum Toxin A (BTA)
Trial: 24286443
Drug: High-cocoa flavanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-cocoa flavanol (CF) intervention (375 mg CF, HiFI)
Trial: 24286443
Drug: Low-cocoa flavanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-cocoa flavanol control (9 mg CF, LoFl)
Trial: 22464260
Drug: MitraClip device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitraClip device treatment
Trial: 20158897
Drug: Cognitive patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive patient education intervention (up to four weekly sessions, each lasting 30 minutes)
Trial: 20158897
Drug: Normal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal treatment (control group)
Trial: 16231532
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of gadolinium (0.2 mmol/kg)
Trial: 16231532
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of gadolinium (0.1 mmol/kg)
Trial: 12669122
Drug: Intravenous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous unfractionated heparin (group A)
Trial: 11877267
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily low‐molecular‐weight heparin (reviparin) for 1 week (group B)
Trial: 11877267
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily reviparin for 4 weeks (group C)
Trial: 7542589
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine from nasal spray
Trial: 7542589
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine from nasal spray with xylometazoline
Trial: 401827
Drug: Disodium ethane‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) at doses of 0, 2.5, 5, 10, or 20 mg/kg/day (randomized)